Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Innate Pharma (IPHA) over the last 8 years, with Q2 2025 value amounting to $282.99.

  • Innate Pharma's Shares Outstanding (Weighted Average) fell 1523.07% to $282.99 in Q2 2025 from the same period last year, while for Jun 2025 it was $282.99, marking a year-over-year decrease of 1523.07%. This contributed to the annual value of $86.6 million for FY2024, which is 5.68% up from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Shares Outstanding (Weighted Average) is $282.99, which was down 1523.07% from $86.6 million recorded in Q4 2024.
  • Innate Pharma's Shares Outstanding (Weighted Average)'s 5-year high stood at $91.0 million during Q4 2021, with a 5-year trough of $21.78 in Q2 2023.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $361.28 (2021), whereas its average is $38.4 million.
  • Per our database at Business Quant, Innate Pharma's Shares Outstanding (Weighted Average) plummeted by 7637.17% in 2022 and then skyrocketed by 143286.68% in 2024.
  • Innate Pharma's Shares Outstanding (Weighted Average) (Quarter) stood at $91.0 million in 2021, then dropped by 10.71% to $81.3 million in 2022, then rose by 6.54% to $86.6 million in 2023, then rose by 0.06% to $86.6 million in 2024, then tumbled by 100.0% to $282.99 in 2025.
  • Its Shares Outstanding (Weighted Average) was $282.99 in Q2 2025, compared to $86.6 million in Q4 2024 and $333.84 in Q2 2024.